Registered forecast

75% registered probability event by 2026-11-25 Unresolved

FDA approves venglustat for type 3 Gaucher disease on or before the disclosed PDUFA goal date of 2026-11-25

FF-027 Registered Unresolved
registered due
Registered probability
75%
Decision by
2026-11-25
Reading window
2026-10-07 → 2026-11-25
Decision stage
  1. 5 Guideline
  2. 6 Regulatory
  3. 7 Coverage
Baselines it has to beat
  • Authority base rate 85%
  • Calendar cycle 80%
  • Analyst proxy 75%

nextconsensus.com/forecast/ff-027/ registry snapshot 2026-11-10 Share image

NextConsensus registered this probability on 2026-10-06. It is one of 36 registered FDA goal-date forecasts.

The proposition

What was registered

The FDA takes an approval action on Sanofi's New Drug Application for venglustat for the treatment of type 3 Gaucher disease, with an approval action date on or before 2026-11-25, the target action date disclosed in Sanofi's 2026 half-year management report, furnished on Form 6-K on 2026-07-30.
Who decides
US Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER) (US)
Who has to act
Rung 6: Regulatory action — Label/indication change, approval action, REMS modification, or withdrawal by FDA, EMA, PMDA, Health Canada, etc.
Counted with
FDA action by goal date
Scope
Type 3 Gaucher disease

The estimate

The number and the baselines it has to beat

75% probability, method v0.1.0 · frozen at the 2026-10-06 cutoff

The estimate that the named body takes the action by the deadline, from what was public at the cutoff.

The alternatives it was registered against, each with the reasoning that produced it. They were set at registration: how often this kind of decision happens on time, what the calendar alone suggests, and a reading of the same public record without this method. Each one's reasoning shows whether it is a count of past decisions or an estimate.

Authority base rate 85%

ESTIMATE FROM THE SHAPE OF THE CLASS, NOT AN ENUMERATED COUNT. Applications built on positive randomized controlled trials are approved at their first goal date in a large majority of cases. The calendar's own met-goal-date share for disclosed PDUFA dates does not exist yet.

Calendar cycle 80%

A clock-only model: the goal date is inside the window, FDA meets most goal dates, and most first-cycle actions on applications like this are approvals. With no evidence input it cannot tell a strong application from a weak one.

Analyst proxy 75%

A rare-disease analyst reading the same filings on 2026-10-01 would weigh priority review, Breakthrough Therapy designation and a phase 3 that met both neurological co-primary endpoints against an active comparator, against a small trial and failures of the same drug in Fabry disease. Estimated by reconstructing that read, not by surveying analysts.

Regulatory action (FDA): offered on judgment, with no calibration figure until 15 in the class have resolved.

The method and every record are public, so you can check the work.

The clock

Dates that constrain the record

Evidence as of
2026-10-06
Nothing after this date informed the estimate.
Registered
2026-10-06
Frozen and hashed.
Reading window
2026-10-07 → 2026-11-25
When the outcome can be read against the rule.
Event by
2026-11-25
The final qualifying action date; the frozen resolution rule defines what counts. Add to calendar
ledger e47801540786a6fe2ed9a4a168e3e7923e30b1e5efe6a34cee6a64d3108081f8
· operator record jc-1791309828469-68a8e289

Around this record

Confidential Asset & Milestone Evaluation

Evaluating an asset or milestone that the FDA could move?

Name the asset, the deciding authority, and the date your team commits to: a P&T review, an HTA submission, a label negotiation, a deal closing, or a milestone dispute. Your stake need not be direct sponsorship — an asset you evaluate, finance, advise on, or rely upon is enough. Every commercial evaluation applies the same rigorous pre-registration and primary-source verification as this record, delivered privately under mutual NDA.

$9,500 · 10 business days One critical milestone, authority, and target date: the dated evidence baseline, authority divergence redline, evidence stall assessment, and transition probability. Delivered within ten business days of the kickoff call, or you don't pay.
100% confidential under NDA Structured to the same auditable standard as this public benchmark — who decides, the resolution rule, and the baselines — while keeping your inquiry and asset strictly private.
Reconstructing a record? For an earnout, milestone dispute, or diligence file: the $35,000 Regulatory & Coverage Diligence Dossier per asset, 15 business days, no probabilities.

Resolution

The rule that settles the forecast

Resolves YES if the openFDA Drugs@FDA records returned by https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22venglustat%22&limit=100 and by https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22VENGLUSTAT%22&limit=100, read together (openFDA does not always fill the generic-name field for a new application), contain an application whose ORIG submission has submission_status AP and a submission_status_date on or before 2026-11-25, and the Drugs@FDA approval letter or label for that application names type 3 Gaucher disease in its indication, with Sanofi or a Sanofi subsidiary as applicant. An approval for a narrower type 3 Gaucher disease population, or for its neurological manifestations only, still resolves YES. Resolves NO if no approval action is dated on or before 2026-11-25: a complete response letter, a goal-date extension, withdrawal or no action. The goal date is frozen as disclosed at the cutoff; a later extension does not move it, and an approval dated after 2026-11-25 resolves NO as occurred_after_deadline. Read no earlier than 2026-12-09. If openFDA has not refreshed by then, the Drugs@FDA web record (https://www.accessdata.fda.gov/scripts/cder/daf/, searched by the name venglustat) governs. The application number was not public at the cutoff, so the rule reads by name; a suffix on the nonproprietary name or a proprietary name does not change the identification. Resolves unresolvable only if none of these sources can be read after the read floor. Resolves VOID, with the reason recorded, only if FDA withdraws every public record of approval actions named above without an equivalent public successor, so that no approval date for this product can be read; while any of them publishes it, the rule stands.

Source the rule names: https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22venglustat%22&limit=100, https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:%22VENGLUSTAT%22&limit=100, https://www.accessdata.fda.gov/scripts/cder/daf/

Readers: Resolver A, clinical methodology; Resolver B, payer evidence. The same two reader roles are assigned to every forecast registered so far.

What this record will show once it resolves

Beside every result, the count for its class (FDA action by goal date): registered, resolved, unresolved, and expired. One forecast is one instance, not a rate.

The finding
As the rule above reads it: occurred on time, did not occur, or left unscored.
The readers and their sources
Two reader roles read the source named above: Resolver A, clinical methodology; Resolver B, payer evidence. Who adjudicated it is named here, with the sources they read when the adjudication lists them. Being named as a reader means applying the frozen rule to the public record; it is not support for the estimate, the method, or NextConsensus.
The number against its baselines
75% beside three baselines, each scored by the same rule (squared error), so a reader can see how the record did against each of them.

Email me when FF-027 resolves

One email when the result is published, then nothing; the address is deleted a month later.

Reasoning

What the number rests on

The facts it was built from are below, as they stood at the cutoff, with every source archived; each baseline above carries the reasoning that produced it. The written mechanism and the conditions that would make the proposition ill-posed were frozen with the record, are held in the ledger, and are covered by its hash.

The state of the record at the cutoff

Recorded as they stood on 2026-10-06.

review pathway
priority review (SRC-001, SRC-002, SRC-003); Breakthrough Therapy and Fast Track designations and US orphan designation for GD3 (SRC-002)
submission type
original NDA for a new investigational molecule (SRC-002)
evidence class
one randomized, double-blind, double-dummy, active-comparator (ERT) Phase 3 study, LEAP2MONO (SRC-002)
pivotal n
43 patients randomized 1:1 (SRC-002)
endpoint type
co-primary: change in SARA modified total score and in RBANS total scale index score vs ERT from baseline to week 52; both met, plus 3 of 4 key secondary endpoints (SRC-002)
approved competitors in class
Sanofi states there are currently no approved targeted treatments that specifically address the neurological symptoms of GD3 (SRC-002); Sanofi's Cerezyme and Cerdelga form its existing Gaucher disease franchise (SRC-001)
months since last guideline revision
not applicable — no guideline is the subject of this proposition
panel cycle position
not applicable — the act is an FDA approval action
sponsor request status
priority review granted May 2026 (SRC-001); NDA submission date not stated
odac referral
none announced in the archived sources
sponsor state change
none recorded

Sources

Everything the estimate was built from

Each was retrieved on or before the 2026-10-06 cutoff and archived at the digest shown. If a publisher edits a page after the fact, the digest stops matching and the substitution is visible.

  1. SRC-001 Sanofi Form 6-K (furnished 2026-07-30), exhibit: 2026 half-year management report (latest Sanofi filing found that states the date). States that in May FDA granted priority review to the NDA for venglustat for type 3 Gaucher disease and that 'The target action date for the FDA decision is November 25, 2026'; also states venglustat did not meet the primary endpoint in the PERIDOT and CARAT Phase 3 studies in Fabry disease.

    https://www.sec.gov/Archives/edgar/data/1121404/000162828026050803/exhibit992-2026halfyearman.htm

    Retrieved 2026-10-01 · sha256 78c671041137febd93622e7c255ef797b21514547b08052e40a3f5fea5134254

  2. SRC-002 Sanofi Form 6-K Exhibit 99.1, furnished 2026-06-08: press release dated May 28, 2026 'Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease'. States the target action date (November 25, 2026), describes the LEAP2MONO Phase 3 study (43 patients randomized 1:1 vs ERT; both primary endpoints and three of four key secondary endpoints met) and prior Breakthrough Therapy, Fast Track and orphan designations.

    https://www.sec.gov/Archives/edgar/data/1121404/000119312526260613/d123884dex991.htm

    Retrieved 2026-10-01 · sha256 521965d2464588178b02140c05830c20821094d8343ca6c03a5393460d430d2a

  3. SRC-003 Sanofi Form 6-K (furnished 2026-07-30), Q2 2026 results press release. Lists 'venglustat – GD3 – priority review (US)' and states the target action date for the FDA decision is November 25, 2026.

    https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm

    Retrieved 2026-10-01 · sha256 71db55bcf24f5a592b5c3720922d820b3d395e155c1bc5ea894afe2f6a16262e

  4. SRC-004 openFDA drugsfda API response for generic name 'venglustat', retrieved 2026-10-01: 404 NOT_FOUND 'No matches found!'.

    https://api.fda.gov/drug/drugsfda.json?search=openfda.generic_name:%22venglustat%22

    Retrieved 2026-10-01 · sha256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da